Pancreatic Cancer Treatment Outcome Predicted By Genetic Test A genetic tool developed in Japan allows clinicians to determine which patients may benefit the most from pancreatic cancer surgery to remove advanced tumors after first undergoing treatment to shrink the tumors. The tumor marker gene (TMG) model involves combining the patients’ genetics with that of their tumor and was able to differentiate between patients who did well after surgery and those who did not. The research team, led by Nagoya University, now wants to further develop the TMG model score they created and to validate it for potential wider use. “We found that the TMG model could more accurately identify which patients would really benefit from surgery. This could prevent some from undergoing unnecessary procedures and offer surgical opportunities to others who might have been overlooked,” said lead investigator Haruyoshi Tanaka from the Department of Surgery at Nagoya University Hospital in a press statement. ...